Td Asset Management Inc Editas Medicine, Inc. Transaction History

Td Asset Management Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 01, 2019	SELL	$20.48 - $27.76 $198,041 - $268,439	-9,670 Closed	0 $0
Q1 2019 May 08, 2019	SELL	$19.43 - $26.41 $141,839 - $192,793	-7,300 Reduced 43.02%	9,670 $236,000
Q4 2018 Feb 01, 2019	SELL	$18.19 - $31.79 $72,760 - $127,160	-4,000 Reduced 19.07%	16,970 $386,000
Q3 2018 Nov 01, 2018	BUY	$27.65 - $38.39 $5,530 - $7,678	200 Added 0.96%	20,970 $667,000
Q2 2018 Jul 31, 2018	BUY	$31.4 - $41.01 $9,420 - $12,303	300 Added 1.47%	20,770 $744,000
Q1 2018 May 11, 2018	BUY	$29.84 - $44.08 $8,952 - $13,224	300 Added 1.49%	20,470 $679,000
Q4 2017 Feb 02, 2018	SELL	$21.89 - $31.34 $188,254 - $269,524	-8,600 Reduced 29.89%	20,170 $620,000
Q3 2017 Nov 09, 2017	BUY	$15.81 - $24.01 $454,853 - $690,767	28,770	28,770 $691,000

248

57M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $90M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Td Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Td Asset Management Inc with notifications on news.